Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Melanoma
  • Skin Neoplasms

abstract

  • : The results confirm that ipilimumab is clinically active in patients with advanced refractory melanoma. The ALC after 2 ipilimumab treatments appears to correlate with clinical benefit and OS, and should be prospectively validated. Cancer 2010. (c) 2010 American Cancer Society.

publication date

  • April 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2917065

Digital Object Identifier (DOI)

  • 10.1002/cncr.24951

PubMed ID

  • 20143434

Additional Document Info

start page

  • 1767

end page

  • 75

volume

  • 116

number

  • 7